Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors.

Bonnie S GlissonRom S LeidnerRobert L FerrisJohn D Powderly Naiyer A RizviBhumsuk KeamReva SchneiderSanjay GoelJames P OhrJennifer BurtonYanan ZhengSteven EckMatthew GribbinKatie StreicherDanielle M TownsleySandip Pravin Patel

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

MEDI0562 was safely administered at doses up to 10 mg/kg in heavily pretreated patients. On-target pharmacodynamic effects were suggested in this setting. Further evaluation with immune checkpoint inhibitors is ongoing.

Keyphrases

monoclonal antibody
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
young adults